Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Histologically or cytologically confirmed solid malignancy that metastatic or unresectable for which standard curative measures do not exist, but for which docetaxel treatment is appropriate.~Exclusion criteria :~* Squamous histology/cytology lung cancer~* Need for a major surgical procedure or radiation therapy during the study~* Treatment with chemotherapy, hormonal therapy, radiotherapy, surgery, or an investigational agent within 28 days~* Cumulative radiation therapy to \>25% of the total bone marrow~* History of brain metastases~* Eastern Cooperative Oncology Group(ECOG)\>1~* Prior docetaxel treatment but have not been appropriate for safety reasons~* Inadequate organ and bone marrow function~* Uncontrolled hypertension~* Evidence of clinically significant bleeding diathesis or underlying coagulopathy~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept/ docetaxel (Type: EXPERIMENTAL): Patients with advanced cancer will receive different doses of aflibercept in combination with approved dose of docetaxel.~Aflibercept 4 or 6mg/kg over 1 hour IV immediately followed by Docetaxel 75mg/m2 IV over 1 hour on Day 1, every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).